<DOC>
	<DOCNO>NCT02215148</DOCNO>
	<brief_summary>To assess pharmacokinetic profile tolvaptan critically ill acute brain injury patient secondarily evaluate clinical response safety tolvaptan acute brain injured patient</brief_summary>
	<brief_title>Pharmacokinetics Clinical Response Tolvaptan Neurocritical Care Patients</brief_title>
	<detailed_description />
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Acute brain injury patient ICU hyponatremia ( Na &lt; 135 mmol/L ) necessitate treatment addition fluid restriction per clinical judgement patient risk worsen cerebral edema 2 . Informed consent obtain patient authorized legal representative 3 . Age ≥ 18 year 1 . Use CYP3A4 inhibitor inducer medication , juice , herbal supplement within 96 hour prior study period . 2 . A positive urine serum pregnancy test , currently breastfeed 3 . Patients subarachnoid hemorrhage patient suspect cerebral salt waste sign volume depletion 4 . Imminent death brain death 5 . Concomitant fungal infection 6 . History HIV 7 . Concomitant administration continuous infusion hypertonic saline , conivaptan hypertonic saline bolus within 24 hour study drug administration 8 . Diuretic mannitol administration within 6 hour 9 . Serum creatinine ≥ 3.5 mg/dL 10 . Diagnosis cirrhosis liver function test &gt; 2x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>